{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"groups":[{"description":"Immune globulin intravenous (IGIV) was administered to patients with cardiac-dominant AL amyloidosis in order to determine its therapeutic potential or possible toxicity when given to subjects weekly for 3 months and then every other week for the next 9 months. Response was evaluated by changes in serum anti-fibril antibody levels, changes in BNP (B-type natriuretic peptide) levels and IVS (interventricular septum) thickness.","id":"OG000","title":"Human Immune Globulin Intravenous (IGIV)"}],"paramType":"NUMBER","populationDescription":"All patients who had at least one infusion of human immune globulin intravenous.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Tolerance for Human Immune Globulin Intravenous (IGIV), as Reflected by the Number and Severity of Toxicity Incidents Occurring in Ten Patients Receiving at Least One Infusion of IGIV.","type":"PRIMARY","unitOfMeasure":"events"}